---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-004971"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-04-16T23:59:59+00:00"
generated_at: "2026-05-23T13:55:43.393849+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharma: Ketamir-2 shows positive preclinical results in diabetic neuropathy rat model

## Summary
- Ketamir-2 significantly reduced neuropathic pain in a rat model of type 2 diabetes (high-fat diet + STZ).
- Some treated animals returned to pre-diabetic baseline sensitivity, indicating full symptom reversal.
- Results confirm oral bioavailability and non-dissociative profile, supporting ongoing Phase I trial in healthy volunteers.
- Company plans to initiate Phase IIa trial in diabetic neuropathy patients by end of 2025.

## SEC filing metadata
- accession: 0001641172-25-004971
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225004971/0001641172-25-004971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225004971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-004971
- JSON: https://secwatch.observer/filing/0001641172-25-004971.json
- Plain text: https://secwatch.observer/filing/0001641172-25-004971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.